Absorption, Metabolism and Excretion of N, N-Bis(phenylcarbamoylmethyl)dimethylammonium Chloride (QX-572) in the Rat

Abstract

The gastro-intestinal absorption and metabolic fate, after intravenous and intraperitoneal administration, of [³H]N, N-bis(phenylcarbamoylmethyl)dimethylammonium chloride (QX-572), a lidocaine derivative with anti-arrhythmic activity, has been investigated in the rat.

Only about one-third of the dose is absorbed after oral administration to fasted animals. Pre-feeding of rats markedly diminishes the apparent availability of the drug. Co-administration of salicylate results in about 50% increase in the absorption of QX-572.

After intravenous administration of [³H]QX-572 to normal rats, urinary excretion of ³H is 60% greater than after intraperitoneal administration. Total urinary recovery of ³H is similar after intravenous or intraperitoneal administration to rats with ligated bile ducts, although much higher than that observed in non-ligated rats.

Urinary excretion data suggest that in normal rats apparent QX-572 is excreted in bile to a much greater extent after intraperitoneal than after intravenous administration. The total cumulative ³H recovered from rat bile 24 h after administration of [³H]QX-572 was about 65% greater after intraperitoneal than after intravenous administration.

One metabolite, possibly a carboxylic acid, was excreted in the urine along with unchanged drug. Irrespective of the route of administration about 70% of the total ³H in the urine represented unchanged drug and the metabolite accounted for the balance. Essentially, no intact drug was found in the bile. The same metabolite as identified in the urine accounted for about 80% of total ³H in the bile.

In the rat QX-572 undergoes significant first-pass metabolism and the metabolite is rapidly cleared from liver to bile.